(firstQuint)Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation.

 This proof-of-concept study is a randomized, parallel design of two different oral doses of QLT091001 compared to placebo to evaluate treatment effects in patients with impaired dark adaptation.

 Approximately 40 subjects will be enrolled in this study at approximately 7 centers in the US.

.

 Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation@highlight

This is a Phase IIa proof-of-concept study to evaluate the effects of oral QLT091001 on adults with impaired dark adaptation.

